Nearly all patients with chronic hepatitis C virus (HCV) infections should receive direct-acting anti-viral agents, according to updated guidelines by the American Association for the Study for Liver Diseases and the Infectious Diseases Society of America.
Based on expanded “real-world” experience with the tolerability and efficacy of newer HCV medications, the section of the website www.HCVguidelines.org on “When and in Whom to Initiate HCV Therapy” no longer includes tables that offer recommendations on how to prioritize patients for treatment.
Read Full Article »